English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background In thalassemia major (TM) patients, major mortality is due to cardiac hemosiderosis. Several types of iron chelating agent available recently are given to overcome this problem Objective To compare cardiac dysfunction in thalassemia major patients who used subcutaneous deferoxamine (DFO) to those who used oral deferiprone (DFP) as an ironchelating agent. Methods This crosssectional study was held at the Thalassemia Center, Department of Child HealthCipto Mangunkusumo Hospital (DCHCMH), Jakarta. We included TM patients aged 1O18 years Mth a mean pretransfused hemoglobin level of 2:.7 g/dL in the prior year, and who had used DFO or DFP for at least 1 year v.ith good compliance, at a standard dose of DFO at 40-60 mg/kg/day for 5 days a week or DFP at 50-100 mg/kg/day. We excluded TM patients v.ith congenital heart disease or overt heart failure. Transthoracal echocardiography was performed at the Integrated Cardiac Service, CMH by a pediatric cardiologist using the conventional method and tissue Doppler imaging (TD I) consecutively, and within 2 weeks of the subject's receiving a packed red blood cell (PREC) transfusion. The 57 TM subjects consisted of 19 DFO users and 38 DFP users. Results In our subjects, diastolic dysfunction was more commonly seen than systolic dysfunction, especially moderate diastolic dysfunction. In the DFO group, diastolic dysfunction only was detected in 3/19 subjects, systolic dysfunction only in 1/19 subjects, and both diastolic and systolic dysfunction in 15/19 subjects. None of the DFO users had normal cardiac function. In the DFP group, diastolic dysfunction only was seen in 6/38 subjects, and both diastolic and systolic dysfunction in 30/38 subjects, while 2/38 subjects had normal cardiac function. Conclusion Diastolic and/or systolic dysfunction was detected in the majority of subjects, but with preserved global cardiac function. We found that cardiac dysfunction was not significantly different in the two iron chelator groups. For all subjects, diastolic dysfunction  was seen in 89% of cases, while systolic dysfunction was detected in 77% of cases. [Paediatr Indones. 2012;52:272,9].

Comparison of cardiac dysfunction in thalassemia major patients using deferoxamine or deferiprone as an iron-chelating agent